Psilocybin for Hospitalized Patients with Treatment-resistant Depression

Phase 2 Recruiting 100 enrolled University Hospital, Ghent Filament Health Corp. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression.

Timeline

Start: 2024-05-21
Primary completion: 2026-03
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Psilocybin	Other / unclassified	25 mg	—

Indications

No indication recorded.